Current status of liposomal anthracycline therapy in metastatic breast cancer

Clinical Breast Cancer

Volumn 4, Issue SUPPL. 2, 2003, Pages

  Rivera, Edgardo ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Anthracyclines; Cardiotoxicity; Liposomal drug delivery; Tolerability

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; LIPOSOME; MITOXANTRONE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TRASTUZUMAB;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANADA; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG USE; EUROPE; FATIGUE; HAND FOOT SYNDROME; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; KAPOSI SARCOMA; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0346343244     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.s.019     Document Type: Article

References (47)

1. Winer EP, Morrow M, Osborne CK, et al. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001:1651-1717.
2. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Breast cancer version 2.2003. Available at: www.nccn.org/physicians/fidelines.html. Accessed June 17, 2003.
3. Esteva FJ, Valero V, Pusztai L, et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001; 6:133-146.
4. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003; 21:588-592.
5. A'Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993; 67:801-805.
6. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125:47-58.
7. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003; 97:2869-2879.
8. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-717.
9. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96:133-139.
10. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15:1318-1332.
11. Allen TM. Liposomes: opportunities in drug delivery. Drugs 1997; 54 (suppl 4):8-14.
12. Lasic DD. Mixed micelles in drug delivery. Nature 1992; 355:279-280.
13. Daunorubicin citrate liposome injection (DaunoXome®) [product information]. San Dimas, CA: Gilead Sciences; 2000.
14. Doxorubicin HCl liposome injection (Doxil®) [product information]. Mountain View, CA: Alza Pharmaceuticals; 2000.
15. O'Bryne KJ, Thomas AL, Sharma RA, et al. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer 2002; 87:15-20.
16. Shapiro CL, Ervin T, Welles L, et al. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. J Clin Oncol 1999; 17:1435-1441.
17. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94:25-36.
18. Valero V, Buzdar AU, Theriault RL, et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 1999; 17:1425-1434.
19. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19:1444-1454.
20. Erdkamp F, Chan S, Davidson N, et al. Phase III study of TLC-99 (liposome encapsulated doxorubicin) plus cyclophosphamide vs. epirabicin (EPI) plus cyclophosphamide (CPA) in patients with metastatic breast carcinoma (MBC). Proc Am Soc Clin Oncol 1999; 18:121a (Abstract #459).
21. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 1997; 54 (suppl 4): 15-21.
22. Ranson MR, Carmichael J, O'Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15:3185-3191.
23. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89:1037-1047.
24. Keller AM, Mennel RG, Nabholtz JM, et al. Phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) for the treatment of patients with advanced breast cancer who have failed a prior taxane-containing chemotherapy regimen. Proc Am Soc Clin Oncol 2001; 20:30a (Abstract #115).
25. Wigler N, Inbar M, O'Brien M, et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21:45a (Abstract #177). Poster presented at: 38th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; May 18-21, 2002.
26. Safra T, Groshen S, Jeffers S, et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer 2001; 91:90-100.
27. Perez AT, Domenech GH, Frankel C, et al. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Invest 2002; 20 (suppl 2):22-29.
28. Gabizon AA, Lyass O. Cardiac safety of pegylated liposomal doxorubicin demonstrated by endomyocardial biopsy in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003;22:763. (Abstract #3067) Poster presented at: 39th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; May 31-June 3, 2003.
29. Rivera E, Valero V, Syrewicz L, et al. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 2001; 19:1716-1722.
30. Rivera E, Valero V, Arun B, et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003; 21:3249-3254.
31. Silverman P, Overmeyer B, Holder L, et al. Doxil™ and intravenous cyclophosphamide as first-line therapy for patients with metastatic breast cancer (MBC): interim results of an ongoing pilot trial. Proc Am Soc Clin Oncol 1999; 18:115a (Abstract #435).
32. Srimuninnimit V, Sinlaratana P, Bhothisuwan K, et al. Phase II study with the combination of pegylated liposomal doxorubicin (Caelyx) and cyclophosphamide (CC) in locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 2002; 21:70a (Abstract #279).
33. Overmoyer B, Silverman P, Holder L, et al. Doxil and intravenous cyclophosphamide as first-line therapy for patients with metastatic breast cancer (MBC): interim results of an ongoing pilot trial. Breast Cancer Res Treat 1998; 50:324 (Abstract #536).
34. Jones V, Finucane D, Rodriguez R, et al. Phase II study of weekly paclitaxel (Taxol) and liposomal doxorubicin (Doxil) in patients with locally advanced and metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19:116a (Abstract #451).
35. Gogas H, Papadimitriou C, Kalofonos P, et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 2002; 13:1737-1742.
36. Lortholary A, Delozier H, Bourgeois C, et al. A phase I study of paclitaxel in combination with pegylated liposomal doxorubicin (PLD) as second-line chemotherapy in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003; 22:52 (Abstract #206).
37. Vorobiof DA, Chasen MR, McMichael GB, et al. Multicentre phase II study with pegylated liposomal doxorubicin (PLD) and paclitaxel (T) as first line therapy in patients (pts) with advanced breast cancer. Proc Am Soc Clin Oncol 2003; 22:49 (Abstract #195).
38. Sparano JA, Malik U, Rajdev L, et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 2001; 19:3117-3125.
39. Alexopoulos A, Ardavanis A, Stavrakakis J, et al. Pegylated liposomal doxorubicin (PLD) and docetaxel (D) as first-line treatment of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003; 22:58 (Abstract #232).
40. Gebbia V, Mauceri G, Fallica G, et al. Pegylated liposomal doxorubicin with escalating dose vinorelbine in metastatic breast carcinoma: a phase I-II clinical investigation. Oncology 2002; 63:23-30.
41. Martin M, Casado A, Garcia-Carbonero I, et al. Phase II study of pegylated liposomal doxorubicin plus vinorelbine in metastatic breast cancer patients with prior anthracycline treatment. Proc Am Soc Clin Oncol 2002; 21:38b (Abstract #1965).
42. Park JW, Stauffer P, Diederich C, et al. Hyperthermia (HT) + Doxil Significantly enhances drug delivery and efficacy in metastatic breast cancer of the chest wall (CW): a phase I/II study. Proc Am Soc Clin Oncol 2001; 20:47a (Abstract #184).
43. Vogel CL, Nabholtz J-M. Monotherapy of metastatic breast cancer: a review of newer agents. Oncologist 1999; 4:17-33.
44. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
45. Theodoulou M, Campos SM, Batist G, et al. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 2002; 21:55a (Abstract #216).
46. Trigo J, Climent MA, Gil M, et al. Cardiac safety and activity of a phase I study of 3-weekly Myocet in combination with weekly Herceptin and paclitaxel in HER2-positive (HER2+) locally advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21:61a (Abstract #242).
47. Wolff AC, Bonetti M, Sparano JA, et al. Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER-2-positive metastatic breast cancer (MBC): preliminary results of the Eastern Cooperative Oncology Group trial E3198. Proc Am Soc Clin Oncol 2003; 22:18 (Abstract #70).